Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial

MLA

Federica Girolami, et al. “Efficacy and Safety of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Osteoarthritis and Cartilage, vol. 28, no. 1, Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5ac709b6c7e5b3230365e9f7ced3e16f&authtype=sso&custid=ns315887.

APA

Federica Girolami, Nadia Brambilla, John Connell, Lucio C. Rovati, T. Blicharski, Massimo D’Amato, Albino Bonazzi, Giampaolo Giacovelli, & Cristina Vitalini. (2019). Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. Osteoarthritis and Cartilage, 28(1).

Chicago

Federica Girolami, Nadia Brambilla, John Connell, Lucio C. Rovati, T. Blicharski, Massimo D’Amato, Albino Bonazzi, Giampaolo Giacovelli, and Cristina Vitalini. 2019. “Efficacy and Safety of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Osteoarthritis and Cartilage 28 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5ac709b6c7e5b3230365e9f7ced3e16f&authtype=sso&custid=ns315887.